Drug Trial Radar · NCT01209949
Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris
Last checked: Nov 20, 2026Latest source record: Aug 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Oct 2010
Primary completion
Jan 2011
Study completion Jan 2011
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Sep 27, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess subjects' experiences using Adapalene BPO gel to treat mild to moderate acne vulgaris using efficacy measurements, quality of life instruments, and video diaries.
Conditions
- Acne Vulgaris
Interventions
Adapalene 0.1% and Benzoyl Peroxide 2.5% gelDrug
Apply adapalene BPO gel once daily in the evening for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Were a Success (Subject's Global Assessment of 'Clear' or 'Almost Clear') at Week 12Time frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Thomas J. Stephens and Associates
Carrollton, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.